| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Edgewise Therapeutics, Inc. (EWTX) have been net sellers, shedding 43,429 shares worth roughly $1.9M on balance.
Counted by filing, the last 12 months brought 1 open-market purchase by 1 insider worth about $199K and 12 sales by 6 insiders worth about $19.5M. The 12 months before that brought 1 open-market purchase by 1 insider worth about $10.0M and 21 sales by 7 insiders worth about $7.2M.
5 of the 12 sales in the last 12 months were made under a Rule 10b5-1 trading plan; the rest were not.
The largest open-market purchase in the last two years was 496,771 shares by Peter A. Thompson (Director, 10% Owner) at an average $20.13 on April 3, 2025, about $10.0M. Twelve months later EWTX was up 145%.
The most recent purchase was by Jonathan C Fox on November 11, 2025.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 52.5K | $1.98M | - | |
| Other | 31.8K | $1.20M | - | |
| Other | 31.5K | $1.19M | - | |
| Dir | 25.1K | $947.3K | - | |
| Dir | 19.8K | $746.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Joanne M. Donovan49 | CMO | Sale+OE | 9,441 | $43.71 | $412,703.17 | -52.3% | - | - | |
| Aug 12, 2026 | Alan J Russell74 | Chief Scientific Officer | Sale+OE | 5,901 | $43.73 | $258,042.47 | -15.8% | - | - | |
| Aug 12, 2026 | Behrad Derakhshan50 | Chief Business Officer | Sale+OE | 5,100 | $43.81 | $223,424.05 | -13.8% | - | - | |
| Aug 12, 2026 | John R Moore | General Counsel | Sale+OE | 5,016 | $43.82 | $219,822.65 | -22.1% | - | - | |
| Aug 12, 2026 | Kevin Koch51 | President and CEO | Sale+OE | 17,971 | $43.68 | $785,042.06 | -25.5% | - | - | |
| Jul 1, 2026 | Alan J Russell74 | Chief Scientific Officer | Sale+OE10b5-1 | 200,000 | $39.41 | $7,881,401.98 | -89.1% | +0.1% | - | |
| May 5, 2026 | Joanne M. Donovan49 | CMO | Sale+OE | 55,230 | $37.88 | $2,092,062.91 | -92.7% | +1.0% | - | |
| Apr 1, 2026 | Joanne M. Donovan49 | CMO | Sale+OE10b5-1 | 28,662 | $32.31 | $926,095.02 | -74.9% | +22.6% | - | |
| Mar 31, 2026 | Joanne M. Donovan49 | CMO | Sale+OE10b5-1 | 21,338 | $32.12 | $685,308.28 | -69.0% | +29.9% | - | |
| Mar 27, 2026 | Joanne M. Donovan49 | CMO | Sell10b5-1 | 16,358 | $30.98 | $506,734.85 | -63.0% | +35.2% | - |